Founders Capital Management lifted its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 1.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,337 shares of the biopharmaceutical company’s stock after buying an additional 480 shares during the quarter. Pfizer makes up 0.4% of Founders Capital Management’s holdings, making the stock its 27th largest position. Founders Capital Management’s holdings in Pfizer were worth $733,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also recently modified their holdings of PFE. Olistico Wealth LLC acquired a new position in Pfizer during the 2nd quarter worth about $25,000. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer in the second quarter valued at approximately $29,000. Quarry LP purchased a new position in shares of Pfizer during the second quarter worth about $31,000. Creekmur Asset Management LLC acquired a new position in Pfizer in the 4th quarter valued at $32,000. Finally, Trivant Custom Portfolio Group LLC grew its stake in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.
Pfizer Stock Performance
Shares of NYSE:PFE traded up $0.62 during mid-day trading on Monday, reaching $29.20. The company had a trading volume of 51,000,551 shares, compared to its average volume of 37,455,102. Pfizer Inc. has a one year low of $25.20 and a one year high of $33.92. The company’s 50-day moving average price is $29.17 and its 200-day moving average price is $28.32. The firm has a market cap of $165.46 billion, a price-to-earnings ratio of -486.83, a PEG ratio of 1.23 and a beta of 0.67. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.
Analysts Set New Price Targets
A number of research analysts have weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Thursday. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Wells Fargo & Company raised their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. StockNews.com downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st. Finally, Barclays lifted their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Nine equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $34.54.
View Our Latest Stock Analysis on PFE
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Recommended Stories
- Five stocks we like better than Pfizer
- What is Forex and How Does it Work?
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- 10 Best Airline Stocks to Buy
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- EV Stocks and How to Profit from Them
- RPM International Thrives in Rate-Cut Driven Construction Rally
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.